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Background: In acute myeloid leukemia (AML), the leukemia initiating cells (LICs) or leukemia stem cells (LSCs) is
found within the CD34+CD38- cell compartment. The LICs subpopulation survives chemotherapy and is most
probable the cause of minimal residual disease (MRD), which in turn is thought to cause relapse. The aim of this
study was to determine the prognostic value of the percentage of LICs in blasts at diagnosis.
Design and methods: The percentage of LICs in the blast population was determined at diagnosis using a unique
Flow-FISH analysis, which applies fluorescent in situ hybridization (FISH) analysis on flow cytometry sorted cells to
distinguish LICs within the CD34+CD38- cell compartment. Fourty-five AML patients with FISH-detectable cytogenetic
abnormalities treated with standardized treatment program were retrospectively included in the study. Correlations
with overall survival (OS), events-free survival (EFS) and cumulative incidence of relapse (CIR) were evaluated with
univariate and multivariate analysis.
Results: The percentage of LICs is highly variable in patients with acute myeloid leukemia, ranged from 0.01% to
52.8% (median, 2.1%). High LIC load (≥1%) negatively affected overall survival (2-year OS: 72.57% vs. 16.75%; P = 0.0037)
and events-free survival (2-year EFS: 67.23% vs. 16.33%; P = 0.0018), which was due to an increased cumulative
incidence of relapse (2-year CIR: 56.7% vs. 18.0%; P = 0.021). By multivariate analysis, high LIC load retained prognostic
significance for OS and EFS.
Conclusions: In the present study, we established the Flow-FISH protocol as a useful method to distinguish normal
and leukemic cells within the CD34+CD38- cell subpopulation. The high percentage of LICs at diagnosis was significantly
correlated with increased risk of poor clinical outcome.
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In acute myeloid leukemia (AML), induction therapy con-
sisting of an anthracycline and cytarabine is still consid-
ered to be the gold standard regimen for younger patients,
resulting in complete remission rates of 50 to 75% [1].
However, relapse is common and the 5-year overall sur-
vival remains less than 40% even after high-dose chemo-
therapy and stem cell transplantation [2]. Relapse likely
originates from minimal residual disease (MRD) cells,
which can be detected after chemotherapy. Consequently,* Correspondence: hu_xiaoxia@126.com; jmwang@medmail.com.cn
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reproduction in any medium, provided the orquantifying MRD in AML, using flow cytometery or
molecular procedures, is of prognostic importance: MRD
frequency after chemotherapy strongly correlates with the
incidence of relapse and survival [3-5].
Acute myeloid leukemia (AML) is a clonal hematologic
malignancy arising from a small population of leukemic
cells that initiate and propagate the disease [6,7]. These
cells are termed leukemic stem cells (LSCs) or leukemia
initiating cells (LICs), which are derived from normal
hematopoietic stem cells or from more mature myeloid
progenitors. LICs are resistant to chemotherapeutic agents
and therefore likely responsible for the outgrowth of MRD,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wang et al. Journal of Hematology & Oncology 2013, 6:85 Page 2 of 8
http://www.jhoonline.org/content/6/1/85which in turn is thought to cause relapse [8]. Since in this
concept the LICs are regarded as the root of MRD and
relapse, detection of leukemia initiating cells at diagno-
sis might offer prognostic value in predicting relapse of
the disease. However, LICs appear to share similar cell
phenotypic characteristics previously identified for nor-
mal HSCs, such as CD34 and CD38, several groups have
reported that some markers are differentially expressed
between the two such as CD90, CLL-1 and IL-3 recep-
tor [9-11]. It is still difficult to distinguish LICs from
their normal counterparts by flow cytometery precisely.
Previous studies have shown that the enrichment of
the CD34+ or CD34+CD38− phenotype in AML at diag-
nosis were associated with a high level of residual disease
after treatment [12,13]. In the present study, we estab-
lished a unique protocol for applying fluorescent in situ
hybridization (FISH) analysis on Fluorescence-activated
cell sorting sorted cells, and separated LICs and normal
HSCs within the CD34+CD38- cell compartment of AML
patients at diagnosis. Our study found that percentage
of FISH-positive CD34+CD38− cells greater than 1% was
strongly correlated with decreases in both events-free
and overall survival in AML patients.Table 1 Characteristics of the 45 AML patients at diagnosis
All patients FISH + CD34





Age, Median(range) 42(14–71) 36(19–
WBC, Median(range) 14.5(0.63-143) 12.4(0.63-
PLT, Median(range) 42(4–191) 28(4–1











FLT3 mutations (%) 5(11.1) 2(10
Allo-HSCT(%) 14(31.1) 6(30
Patients were stratified into favorable (cases with t(8;21), or inv(16), excluding comp
unrelated abnormalities, t(6;9) or 11q23 abnormalities [excluding t(9;11)]), and interMethods
Patients
In this study we included 45 de novo AML patients
(25 male, 20 female) with a median age of 42 years
(range, 14–71), admitted in the Institute of Hematology,
Changhai hospital, between June 2010 and October 2012
(Table 1). Patients with a history of myelodysplastic
syndrome or therapy-related AML as well as acute pro-
myelocytic leukemia were not included. The patients
had the following cytogenetic abnormalities: t(8; 21)
(n = 22), inv(16) (n = 6), trisomy 8 (n = 5), MLL rearrange-
ment (n = 3), trisomy 21 (n = 2), 7q- (n = 2), 9q- (n = 2)
and t(6;9) (n = 1). (Additional file 1: Table S1) All research
samples represented excess bone marrow collected at
diagnosis. The present study was approved by the
Changhai Hospital Institutional Review Board and signed
informed consent was obtained from each patient in
accordance with the Declaration of Helsinki.
Treatments
Induction treatment comprised Daunorubicin (DNR) at
45–60 mg/m2/d or Idarubicin (IDA) at 8-10 mg/m2/d by
30-minute IV infusion on days 1 to 3 and Cytarabine+ CD38- FISH + CD34 + CD38- P value
≥1%



















lex cytogenetic), poor (cases with complex cytogenetic changes three or more
mediate (cases with t(9;11), trisomy 8, 7q-, 9q-, or trisomy 21) risk groups.
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http://www.jhoonline.org/content/6/1/85(Ara-C) at 100 mg/m2/d by continuous IV infusion from
days 1 to 7 (DA regimen). In patients not reaching CR
after 2 courses of DA, a salvage course (FLAG), con-
sisted of five days of treatment with a 30-minute infusion
of fludarabine (Flu) 30 mg/m2/d followed, four hours later,
by a 4-hour infusion of Ara-C 2 g/m2/d, was given. Gran-
ulocyte colony-stimulating factor (G-CSF) 300 μg/day s.c.
was administered 12 hours before starting fludarabine,
for five days and then continued after the end of therapy
until myeloid recovery. Patients reaching CR then
received 4 monthly consolidation cycles with Ara-C at
2 g/m2/12 h by 2-hour IV infusion for 3 days, followed
by G-CSF starting at day 8 or neutrophile counts less
than 1 × 109/L until neutrophil recovery. Patients with
CNS disease received triple intrathecal infusions (metho-
trexate 10 mg, cytarabine 50 mg, dexamethasone 5 mg)
twice a week until disappearance of blast cells in the
cerebrospinal fluid. Patients were candidates for allogen-
eic hematopoietic stem cell transplantation (allo-HSCT)
in first CR if they had a matched sibling or ≥9/10 HLA
allele fully matched unrelated donor. Standard myeloa-
blative or reduced-intensity conditioning regimens were
allowed, depending on the patient age and health status.
Of all patients, 14 patients received allo-HSCT during
the follow-up period.Flow cytometry and cell sorting
Mononuclear cells (MNCs) were isolated from bone mar-
row aspirates, collected at diagnosis, by density gradient
centrifugation (Ficoll-Paque, GE Healthcare Life Sciences).
The experiments were done on fresh cells. Primary AML
cells were washed and resuspended into 100 μl of cold
(4°C) Phosphate Buffered Saline solution (PBS) + 2%
fetal calf serum (FCS) and incubated for 30 minutes
on ice with combinations of fluorescein isothiocyanate-
(FITC), Peridinin-Chlorophyll-Protein Complex-Cy5.5-
(PerCP-CY5.5), phycoerythrin- (PE), phycoerythrin-Cy7-
(PE-CY7), allophycocyanin (APC)-labeled monoclonal
antibodies (MoAbs). Anti-CD45 PerCP-CY5.5, anti-CD19
APC, anti-CD7 FITC, anti-CD33 PE-CY7, anti-CD13 PE,
anti-CD10 APC, anti-CD34 FITC, anti-HLA-DR PE-CY7,
anti-CD117 PE, anti-cCD3 APC, anti-MPO FITC, anti-
cCD79a PE, anti-CD14 APC, anti-CD64 FITC, anti-CD2
PE-CY7, anti-CD11c PE, anti-CD15 FITC, anti-CD56 PE-
CY7, anti-CD66c PE, anti-CD34 APC, anti-CD11b FITC,
anti-CD38 PE-CY7 and anti-CD123 PE MoAbs were all
from BD Biosciences (San Jose, CA). After antibody stain-
ing, cells were washed with cold PBS, resuspended in 1 ml
of cold PBS and stained for 5 minutes with 2 μg/ml propi-
dium iodide (Sigma-Aldrich), enabling exclusion of dead
cells. Cells were kept on ice until fluorescence-activated
cell sorting (FACS) analysis. Data acquisition was performed
using a FACSAira flow cytometery with BD FacsDiVasoftware (BD Biosciences, Franklin Lakes, NJ, USA) at
the Institute of Hematology, Flow Cytometry Core.
To sort the stem cell subpopulation, a total of 1 × 106
primary AML MNCs was stained with the following
conjugated antibodies: monoclonal PE-conjugated anti-
CD34, FITC-conjugated anti-CD38 and APC-conjugated
anti-CD45 (BD Biosciences). Gates were set to detect
the CD34+CD38- cells as shown in Figure 1. Cells were
sorted using a FACSAria flow cytometery. Cells were
kept on ice during the whole procedure. Purity of sorted
populations was >99%.
Flow-fish analysis
As part of the diagnostics for AML, chromosome analyses
(G-banding) and FISH were performed on diagnostic BM
samples of all AML patients. For Flow-FISH analysis,
1000 to 3000 cells from CD34 + CD38- cell subpopula-
tion were directly sorted into 20 μL drops of PBS that
were placed on a grease-free glass slide. The cells were
then fixed with 3:1 methanol-glacial acetic acid (Sigma-
Aldrich). Air-dried slides were analyzed by FISH in our
laboratory, using probes specific for the patient’s known
cytogenetic abnormality (Abbot Molecular).
Probes were denatured and hybridized according to
manufacturer’s instructions. For evaluation of the Flow-
FISH results, hybridization and deletion signals were scored
in 500 interphase nuclei with an Axioscop 20 (Carl Zeiss,
Jena, Germany) fluorescence microscope with three single-
band-pass filters and one triple-band-pass filter. The images
were captured with a digital camera using CytoVision 4.1
software (Applied Imaging Corp., Newcastle, U.K.). Results
were expressed as percentage FISH-positive cells relative to
number of cells analyzed.
Statistics
Complete response and relapse rates were defined accord-
ing to the Cheson criteria [14]. Pair-wise comparisons be-
tween patients’ characteristics (covariates) were performed
using the Mann–Whitney test or Kruskal-Wallis test for
continuous variables and with the Fisher’s exact test for
categorical variables. Overall survival (OS) was measured
from the date of diagnosis until death or last follow-up
and events-free survival (EFS) from the date of complete
remission (CR) until death, relapse or last follow-up, re-
spectively. Patients alive in complete remission were cen-
sored at the time of last contact. Overall and events-free
survival rates were estimated by the Kaplan-Meier method
and compared using the log-rank test [15]. The cutoff
value for FISH+CD34+CD38- was chosen at a percentage
that resulted in the largest difference in survival between
the two groups defined by that cutoff. In computations of
the cumulative incidence of leukemic relapse (CIR), death
and relapse were included as competing events; survival
was counted as a censored event. The CIR was compared
Figure 1 Flow-FISH strategy results for representative patients with AML1/ETO (A) (sample #9) and CBFβ/MYH11 (B) (sample #21) in
the blast population are illustrated.
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determined by the method of Kalbfleisch and Prentice [16].
Hazard ratios are given with 95% confidence intervals (95%
CI). Survival-time data (events-free survival and overall sur-
vival) and covariates (age, leukocyte count, karyotype, FLT3
mutations and percentage of CD34+CD38−FISH+ cells)
were analyzed using the method of backward Cox pro-
portional hazards regression. All calculations were per-
formed using the R 2.7.2 software package.
Results
Patient characteristics are shown in Table 1. The whole
cohort comprised 45 patients with AML with FISH-
detectable cytogenetic abnormalities. Distribution of karyo-
type was provided in Additional file 1: Table S1. After 1 or
2 courses of induction therapy, CR was obtained in 39
patients (86.7%), 2 (4.4%) was not in remission (> 20%
blast cells in the bone marrow), and 4 (8.9%) patient
died due to febrile neutropenia and sepsis during the
course of induction therapy. In the 39 patients achieving
CR, 30 (76.9%) were assigned to consolidation therapy
consisted of a four- to five-cycle (2 g/m2/12 h for 3 days)cytarabine-based chemotherapy, while the rest 9 (23.1%)
patients received allogeneic hematopoietic stem cell
transplantation after two- or three-cycle cytarabine-based
chemotherapy. The median follow-up time for survival
was 12 months (range: 1–27). After 24 months, 12 pa-
tients (26.7%) had experienced relapse, whereas 7 patients
(17.9%) had died due to non-relapse treatment-related
complications, 3 from treatment-related complications of
transplantation and 4 from infection after chemotherapy
(Table 2).
LIC assessment by flow-fish
To distinguish normal and leukemic cells within the
CD34+CD38− cell compartment, we established a unique
protocol for conducting FISH on flow-sorted cells. Briefly,
CD34+CD38- populations from AML patients at diagnosis
with FISH-detectable cytogenetic abnormalities were sorted
onto glass slides. We could sort as few as 1000 cells on
slides, from which at least 500 cells were successfully
scored by FISH. Results were calculated as the percentage
of FISH-positive cells relative to number of cells analyzed,
and the median level was 68.2% (range, 7.8%-89.6%).
Table 2 The treatment outcome according to LIC Level
Characteristics Low LIC load High LIC load P value
N = 20 N = 25
Failure of induction therapy 2(10%) 4(16%) 0.678
Overall CR 18(90%) 21(84%) 0.678
Overall relapse 2/18(11.1) 10/21(47.6) 0.018
Treatment-related mortality 2/18(11.1) 5/21(23.8) 0.418
2-year OS 0.7257[0.4082, 0.8916] 0.1675[0.0323, 0.3947] 0.000
2-year EFS 0.6723[0.3262, 0.8687] 0.1633[0.0328, 0.3825] 0.003
2-year CIR 56.7% ± 5.1% 18.0% ± 1.5% 0.021
Figure 2 Comparison of overall survival (A) and events-free
survival (B) of AML patients according to FISH + CD34 + CD38-
percentage. A FISH+CD34+CD38- percentage of over 1% was
found to be significantly associated with decreased OS and EFS.
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Patient #21 CBFβ/MYH11) are illustrated in Figure 1.
Outcome according to LIC levels
The percentage of leukemia initiating cells (FISH+CD34+
CD38-) was then quantified as the value of the percent-
age of FISH-positive cells multiplies the percentage of
CD34+CD38-cells in the blast (CD45dimSSClow). The
percentage of FISH+CD34+CD38- cells was evaluated in
45 primary AML samples at diagnosis. The median ex-
pression of CD34+CD38- was 3.3% in the blast (range,
0.1–52.8%). The FISH+CD34+CD38- cells were rare in
the newly diagnosed AML patients, constituting a median
of only 2.31% (n = 45, range, 0.01%-29.4%) of the total blast
cells. According to the LIC level detected by Flow-FISH
analysis, patients were categorized into the two groups: low
LIC (<1%) and high LIC (≥1%), representing 44.4% and
55.6% of all patients, respectively. The clinical character-
istics of the patients are provided in Table 1. Compari-
son of clinical and laboratory characteristics showed no
significant differences between two groups in age, gen-
der, white blood cell (WBC) count, platelet (PLT) count,
blast percentage, FAB subtype distribution, FLT3 muta-
tion status and cytogenetics risk at diagnosis (Table 1).
To determine the prognostic impact of detecting LIC
load at diagnosis, we analyzed the treatment outcome
for 45 patients enrolled in a standardized treatment pro-
gram (Table 2). The 2-year overall survival for patients
with low LIC load was 0.7257[0.4082, 0.8916], compared
with 0.1675[0.0323, 0.3947] for the patients with high
LIC load (P = 0.0037). And 2-year events-free survival were
0.6723[0.3262, 0.8687] versus 0.1633[0.0328, 0.3825],
respectively (P =0 .0018) (Figure 2).
Events, including relapse and death, were more frequent
in patients with a high LIC load. Among 21 patients who
received CR with a high LIC load, 10 (46.7%) experienced
a relapse; among 18 patients who achieved CR with a low
LIC load, 2 (11.1%) experienced relapse (P = 0.018). 5
treatment related death (TRD) (23.8%) occurred in the21 patients who achieved CR with a high LIC load,
whereas 2 TRD (5.6%) occurred in the 18 patients who
received CR with a low LIC load (P = 0.418). The esti-
mated 2-year cumulative incidence of leukemic relapse
for patients with high LIC load was 56.7% ± 5.1% versus
Figure 3 Cumulative incidence of relapse. A FISH+CD34+CD38-
percentage of over 1% was found to be significantly associated with
higher CIR.
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(Figure 3).
Multivariate analysis of the prognostic value of flow-fish
In a univariate analysis of recognized prognostic factors,
including age, FLT3 mutation status, leukocyte count,
cytogenetics and allo-HSCT, cytogenetics were found to
be significantly associated with overall survival (P = 0.01),
whereas the leukocyte count, age, karyotype, FLT3 muta-
tion status and allo-HSCT had no impact on events-free
survival. We next performed a multivariate Cox propor-
tional hazards model for OS and EFS, a percentage of LIC
load of over 1% at diagnosis remained the significant pre-
dictor of outcome (P = 0.003 for OS; P = 0.004 for EFS)
(Tables 3 and 4).
Discussion
AML is a highly heterogeneous disease from the biological
and clinical standpoint, for which prognostic factors have





FLT3 mutation 0.363 0.486[0
WBC≥ 50 × 109 0.250 1.763[0
Cytogenetics 0.010 2.046[1
Allo-HSCT 0.228 1.810[0
FISH + CD34 + CD38-≥ 1% 0.009 4.319[1.
P of the univariate analysis is the P value of the log rank test. HR is the value of the
from 45 patients were complete and were included in the Cox proportional-hazardof therapeutic procedures. Currently, cytogenetic and mo-
lecular aberrations are the best prognostic indicators for
AML patients [17]. However, these factors predict primar-
ily for groups of patients and cannot prognosticate well
for individual patients within any given risk strata. For
example, CBF cytogenetic abnormalities are generally
considered favorable; yet approximately half of these
patients relapse [18-20]. So, new prognostic tools based
on biological analyses need to be developed.
AML is regarded as a stem cell disease, and the failure
of chemotherapy in eradicating primitive leukemia initiat-
ing cells likely contributes to the relapse of AML. Numer-
ous studies have emphasized the correlation between the
enrichment of the CD34+CD38- phenotype in AML at
diagnosis and a high level of residual disease after
treatment [12,13]. And it is generally accepted that
CD34+CD38- cells are enriched for LICs, however, this
population is heterogeneous and includes both normal
and leukemic stem cells. In this regard, measure of
“real” LICs promises to serve as a powerful, individu-
alized prognostic tool, enhancing delivery of risk-adapted
therapies. Recent data have generated important advances
in the field, including the identification of novel leukemia
initiating cells-specific cell surface antigens. Several stud-
ies have showed that the aberrant expression of specific
markers on the cell surface of leukemia progenitors is
characteristic for LIC, differentiating them from their nor-
mal counterparts, including CD90, CD123, CLL-1, CD96,
CD47, Tim3 and so on [8-11]. However, aberrant marker-
positive CD34+CD38- cells at diagnosis are partly of ma-
lignant origin, while the corresponding marker-negative
population is not totally of normal origin. For example,
Rhenen et al. reported that CD123 seems not very useful
in leukemic stem cell detection due to the high expression
of CD123 in normal control samples [21].
In the present study, we established the Flow-FISH
protocol as an effective method to distinguish normal
and leukemic cells within the CD34+CD38- cell subpopula-
tion. As leukemic cytogenetic marker was never present inl
Cox regression
HR P HR
% CI 95% CI
.898, 5.276] 0.562 1.393[0.454, 4.278]
.103, 2.297] 0.644 0.639[0.096, 4.275]
.670, 4.636] 0.105 2.844[0.802, 10.085]
.190, 3.519] 0.068 1.914[0.953, 3.846]
.689, 4.754] 0.015 4.581[1.338, 15.684]
436, 12.987] 0.003 7.048[1.918, 25.899]
hazard ratio. 95% CI is the 95% confidence interval of the hazard ratio. Data
s regression.
Table 4 Analysis of covariates associated with events-free survival
Univariate analysis Cox regression
P HR P HR
95% CI 95% CI
Age 0.473 1.428[0.540, 3.780] 0.914 0.933[0.265, 3.287]
FLT3 mutation 0.109 0.267[0.053, 1.340] 0.310 0.375[0.056, 2.494]
WBC ≥ 50 × 109 0.466 1.469[0.523, 4.131] 0.417 1.645[0.494, 5.484]
Cytogenetics 0.100 1.620[0.912, 2.875] 0.097 1.854[0.893, 3.847]
Allo-HSCT 0.508 1.371[0.538, 3.496] 0.092 2.674[0.853, 8.389]
FISH + CD34 + CD38- ≥ 1% 0.005 4.955[1.621, 15.148] 0.004 6.354[1.806, 22.356]
P of the univariate analysis is the P value of the log rank test. HR is the value of the hazard ratio. 95% CI is the 95% confidence interval of the hazard ratio. Data
from 39 patients were complete and were included in the Cox proportional-hazards regression.
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“real” LIC load in leukemic burden through Flow-FISH ana-
lysis for patients with recurrent cytogenetic abnormalities.
We showed that this leukemia initiating cells subpopulation
was not so rare in patients, and we found that FISH+CD34+
CD38− cells ranged from 0.01% to 52.8% in the bulk of
blasts. Although the results of the present finding need to
be confirmed in a larger cohort, our data do show that a
high LIC load at diagnosis determines a high relapse rate of
leukemia and a poor clinical outcome. A percentage of
FISH+CD34+CD38− cells of more than 1% is strongly asso-
ciated with reduced OS and EFS suggesting that residual
disease is likely to be high in these patients. Hence, the as-
sessment of the level of FISH+CD34+CD38− cells at diagno-
sis could help clinicians to identify patients as an effective
prognostic indicator in AML with recurrent chromosomal
abnormalities, eg. CBF-AML (Data not shown), and thereby
refining the selection of therapeutic strategies and, possibly,
long-term clinical outcome.
This ability to distinguish these cell populations offers
the potential to simultaneously observe the efficacy of
chemotherapy drugs against putative LICs and their tox-
icity against normal HSCs. It may also facilitate better
identification of therapeutic targets. Recently, Minderman
et al. reported a unique technology to perform FISH in
suspension [22]. The ability to visualize and perform
photometric/morphometric analysis of imagery from
tens of thousands of cells thus combines quantitative
image analysis with the statistical power of flow cytome-
try, may further enhance the sensitivity and specificity
of LIC detection.
To the best of our knowledge, Flow-FISH is used, for
the first time, to detect LIC subpopulation in human
bone marrow samples. In accordance with our results,
high levels of “real” LIC load detected at diagnosis in
AML patients treated with standard chemotherapy, was
significantly correlated with increased risk of poor clinical
outcome. However, it is still not clear if the prognosticvalue of the LIC load detected with Flow-FISH is associated
with the risk stratification of the associated cytogenetic
abnormality and other known gene mutations such as
FLT3-ITD because, most probably, of the limited cases
in this cohort. Future larger cohort studies should solve
this issue. In conclusion, Flow-FISH discrimination of
leukemic and normal candidate stem cells could be used
as a powerful tool to predict clinical outcome and help
physicians to evaluate criteria for treatment in AML
with recurrent cytogenetic abnormalities.
Findings
Flow-FISH protocol was a useful method to distinguish
normal and “real” leukemic initiating cells within the
CD34+CD38- cell subpopulation. And high LIC Load at
diagnosis was significantly correlated with increased risk
of poor clinical outcome.
Additional file
Additional file 1: Table S1. FISH-detectable cytogenetic abnormalities
of the 45 patients included in this study.
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